Treatment of bullous pemphigoid with rituximab: Critical analysis of the current literature

Journal of Drugs in Dermatology

Volumn 12, Issue 6, 2013, Pages 672-677

  Shetty, Shawn ^a   Ahmed, A Razzaque ^a  

^a Center for Blistering Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

BULLOUS PEMPHIGOID; CARDIOTOXICITY; DRUG FATALITY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOLOGY; REVIEW; SEPSIS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHILD; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; MALE; PEMPHIGOID, BULLOUS; TREATMENT OUTCOME;

EID: 84878659729     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Yancey KB, Egan CA. Pemphigoid: clinical, histological, immunopathologic, and therapeutic considerations. JAMA. 2000;284(3):350-356.
2. Fisler RE, Saeb M, Liang MG, Howard RM, McKee PH. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature. Am J Dermatopathol. 2003;25(3):183-189. (Pubitemid 36706458)
3. Olasz EB, Yancey KB. Bullous pemphigoid and related subepidermal autoimmune blistering diseases. Curr Dir Autoimmun. 2008;10:141-166.
4. Gea-Banacloche JC, Opal SM, Jorgensen J, Carcillo JA, Sepkowitz KA, Cordonnier C. Sepsis associated with immunosuppressive medications: an evidence-based review. Crit Care Med. 2004;32(11 Suppl):S578-S590. (Pubitemid 39489032)
5. Schiavo AL, Puca RV, Ruocco V, Ruocco E. Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: Facts and controversies. Clin Dermatol. 2010;28(3):337-343.
6. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321-327. (Pubitemid 34438839)
7. Nigam R, Levitt J. Where does rituximab fit in the treatment of autoimmune mucocutaneous blistering skin disease? J Drugs Dermatol. 2012;11(5):622-625.
8. Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009;9(1):10-25.
9. Lourari S, Herve C, Doffoel-Hantz V, et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol. 2011;25(10):1238-1240.
10. Saouli Z, Papadopoulos A, Kaiafa G, Girtovitis F, Kontoninas Z. A new approach on bullous pemphigoid therapy. Ann Oncol. 2008;19(4):825-826. (Pubitemid 351461060)
11. Reguiaï Z, Tchen T, Perceau G, Bernard P. Efficacy of rituximab in a case of refractory bullous pemphigoid. [Article in French.] Ann Dermatol Venereol. 2009;136(5):431-434.
12. Saraceno R, Citarella L, Spallone G, Chimenti S. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. Clin Exp Dermatol. 2008;33(2):154-155. (Pubitemid 351197207)
13. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011;65(3):552-558.
14. Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007;156(2):352-356. (Pubitemid 46095965)
15. Schulze J, Bader P, Henke U, Rose MA, Zielen S. Severe bullous pemphigoid in an infant -successful treatment with rituximab. Pediatr Dermatol. 2008;25(4):462-465.
16. Szabolcs P, Reese M, Yancey KB, Hall RP, Kurtzberg J. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant. 2002;30(5):327-329.
17. McGinness JL, Bivens MM, Greer KE, Patterson JW, Saulsbury FT. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) associated with pemphigoid nodularis: a case report and review of the literature. J Am Acad Dermatol. 2006;55(1):143-148. (Pubitemid 43867017)
18. Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin. 2011;29(3):427-438.
19. Fisler RE, Saeb M, Liang MG, Howard RM, McKee PH. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature. Am J Dermatopathol. 2003;25(3):183-189. (Pubitemid 36706458)
20. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825-2833. (Pubitemid 28363048)
21. U.S. Food and Drug Administration. Office of Medical Products and Tobacco. Available at: http://www.fda.gov/AboutFDA/CentersOffices/ OfficeofMedical-ProductsandTobacco/CDER/ucm095666.htm. Accessed April 5, 2013.
22. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232.
23. U.S. Food and Drug Administration. FDA News Release. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251946.htm. Accessed April 5, 2013.
24. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-2581. (Pubitemid 38758544)
25. Meurer M. Immunosuppressive therapy for autoimmune bullous diseases. Clin Dermatol. 2012;30(1):78-83.
26. Kasperkiewicz M, Schmidt E. Current treatment of autoimmune blistering diseases. Curr Drug Discov Technol. 2009;6(4):270-280.
27. Gürcan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol. 2009;161(4):723-731.
28. Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci. 2009;1173:683-691.
29. Feldman RJ, Ahmed AR. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. Expert Rev Clin Immunol. 2011;7(4):529-541.
30. Cooper HL, Healy E, Theaker JM, Friedmann PS. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). Clin Exp Dermatol. 2003;28(4):366-368. (Pubitemid 36801837)
31. Mease PJ. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J Rheumatol. 2008;35(7):1245-1255. (Pubitemid 352000767)
32. Perosa F, Prete M, Racanelli V, Dammacco F. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med. 2010;267(3):260-277.
33. Leon DA. Trends in European life expectancy: a salutary view. Int J Epidemiol. 2011;40(2):271-277.
34. Minino AM, Murphy SL. Death in the United States, 2010. NCHS Data Brief. 2012;99:1-8.
35. Jung M, Kippes W, Messer G, Zillikens D, Rzany B. Increased risk of bullous pemphigoid in male and very old patients: A population-based study on incidence. J Am Acad Dermatol. 1999;41(2 Pt 1):266-268. (Pubitemid 29379717)
36. Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66(3):479-485.
37. F. Hoffmann-La Roche Ltd. Media Release. http://www.roche.com/med-cor- 2006-03-01. Accessed April 5 2013.
38. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793-2806. (Pubitemid 44497758)
39. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006:26;355(17):1772-1779.
40. Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology. 2010;117(5):861-869.
41. Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford). 2007;46(4):626-630 (Pubitemid 46523308)
42. Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49(9):1683-1693.
43. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an openlabel extension analysis. Arthritis Rheum. 2007;56(12):3896-3908. (Pubitemid 350262316)
44. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54(3):723-732.
45. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(2):613-620. (Pubitemid 43228639)
46. Emery P, Mease PJ, Rubbert-Roth A, et al. Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology (Oxford). 2011;50(12):2223-2232.
47. Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis. 2012;71(Suppl 2):i2-i45.
48. Li F, Jin HZ, Su F, Jia L, Sun QN. Pneumocystis pneumonia in patients with immunobullous dermatoses. Int J Dermatol. 2011;50(9):1144-1149.
49. Lehman JS, Murrell DF, Camilleri MJ, Kalaaji AN. Infection and infection prevention in patients treated with immunosuppressive medications for autoimmune bullous disorders. Dermatol Clin. 2011;29(4):591-598.
50. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(9):2625-2632.
51. Garypidou V, Perifanis V, Tziomalos K, Theodoridou S. Cardiac toxicity during rituximab administration. Leuk Lymphoma. 2004;45(1):203-204.
52. Armitage JD, Montero C, Benner A, Armitage JO, Bociek G. Acute coronary syndromes complicating the first infusion of rituximab. Clin Lymphoma Myeloma. 2008;8(4):253-255.
53. Siano M, Lerch E, Negretti L, et al. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. Clin Cancer Res. 2008;14(23):7935-7939.
54. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(6):545-552. (Pubitemid 47236279)
55. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts dual effects in pemphigus vulgaris. J Invest Dermatol. 2008;128(12):2850-2858
56. Bernal I, Domènech E, García-Planella E, Cabré E, Gassull MA. Opportunistic infections in patients with inflammatory bowel disease undergoing immunosuppressive therapy. [Article in Spanish.] Gastroenterol Hepatol. 2003;26(1):19-22. (Pubitemid 36168871)
57. Schmaldienst S, Horl WH. Bacterial infections during immunosuppression - immunosuppressive agents interfere not only with immune response, but also with polymorphonuclear cell function. Nephrol Dial Transplant. 1996;11(7):1243-1245. (Pubitemid 26241408)